TIDMOPTI

RNS Number : 9998K

OptiBiotix Health PLC

28 September 2016

OptiBiotix Health plc

("OptiBiotix" or the "Company")

Appointment of Broker

OptiBiotix Health plc (AIM: OPTI), a Life Sciences business developing compounds to tackle obesity, high cholesterol and diabetes announces that it has appointed finnCap as its sole broker with immediate effect.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information:

 
 OptiBiotix Health plc                                                         www.optibiotix.com 
 Stephen O'Hara, Chief Executive                                             Contact via Walbrook 
                                                                                            below 
 
 Cairn Financial Advisers                                                      Tel: 020 7148 7900 
  LLP (Nominated Adviser) 
 Liam Murray / Jo Turner 
 
 finnCap (Sole Broker) 
 Adrian Hargrave / Scott Mathieson                                                       Tel: 020 
  / Kate Bannatyne (Corporate Finance)                                                  7220 0500 
 Tony Quirke (Corporate Broking) 
 
 Walbrook PR Ltd                                  Tel: 020 7933 8780 or optibiotix@walbrookpr.com 
 Anna Dunphy                                                                   Mob: 07876 741 001

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen(R) and OptiBiotic(R) platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

This information is provided by RNS

The company news service from the London Stock Exchange

END

APPLLFLRADIDFIR

(END) Dow Jones Newswires

September 28, 2016 02:01 ET (06:01 GMT)

Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Optibiotix Health Charts.
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Optibiotix Health Charts.